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factors affecting local control and survival
Nicolaus HJ Andratschke1,5,6*, Carsten Nieder2,3, Franz Heppt6,7, Michael Molls6 and Frank Zimmermann4
Abstract
Purpose: To report on outcome and toxicity of stereotactic body radiotherapy (SBRT) for liver metastases in patients
not eligible for surgery.
Methods: From 2000 to 2009, 74 patients with 91 liver metastases from different primaries have been treated
with SBRT at our institution. Median planning target volume was 123 ccm (range: 10.6-1074 ccm). Treatment
consisted of 3–5 fractions with 5–12.5 Gy/ fraction prescribed to the surrounding 60-95% isodose with daily
image guidance. Regular follow-up included CT or MRI imaging until tumor progression.
Results: Median local recurrence-free interval was 23 months with a local control rate of 74.7%, 48.3% and 48.3%
after 1, 2 and 3 years. Only minimum biologically effective dose (BED) to gross tumor volume (GTV) remained as
independent significant factor for local control in multivariate analysis. No local recurrences were observed in
lesions (n = 12) which received a minimal BED to the GTV of 120 Gy. Including 26 local recurrences, 67 patients
(91%) showed disease progression after SBRT with a median time of 5 months. Median overall survival was 27 months
with survival rates of 77%, 30% and 27% at 1, 3 and 5 years. On multivariate analysis only GTV volume remained
as independent significant prognostic factor for overall survival (p = 0.002). No grade 3 to 5 acute toxicity and no
grade 4 or 5 late toxicity occurred.
Conclusion: SBRT for liver metastases was well tolerated in this non-selected patient cohort and yielded good
local control despite the considerable size of most lesions treated. Long-term survival is possible after SBRT.
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Introduction
Metastatic spread to the liver is quite a frequent event in
the natural course of many common solid tumors [1-3].
Besides primary tumor site, histology, and extent of hep-
atic lesion(s), the presence of additional uncontrolled
metastatic spread profoundly affects prognosis. In colo-
rectal cancer, it has been shown that long term survival
can be achieved with surgical treatment of solitary liver
metastases as the only site of distant relapse [4,5]. Five-
year survival rates in the order of 50% have been
reported in highly selected patients [6]. Therefore, a
treatment strategy focusing on effective local treatment
may be indicated after proper patient selection. In more
advanced, undoubtedly palliative cases, especially with
other metastatic sites present - which may be stable on
effective systemic treatment- local control of otherwise
progressing liver metastases still may be necessary. In
these patients with so-called oligo-progression, one
tends to avoid aggressive surgical intervention. Thus,
other effective approaches for local treatment need to be
explored. The liver is one of the more radiosensitive or-
gans with a low tolerance to large volume irradiation
with regards to effective cytoablative radiation doses [7].
Therefore, radiotherapy has long been neglected as a lo-
cally effective and thus potentially curative or palliative
alternative approach to resection or other invasive pro-
cedures like radiofrequency or laser ablation, cryosurgery
or chemoembolisation.
Over the past 10 years, with rapid development of ex-
tracranial stereotactic radiation techniques and increas-
ing knowledge of the radiobiology of the liver, especially
tolerance to highly focused cytoablative radiation doses,
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stereotactic radiotherapy delivered either as single frac-
tion or hypofractionated treatment has emerged as a
promising alternative to surgical or interventional op-
tions in metastatic disease to the liver [8-13].
At the time of study initiation (year 2000), scarce clinical
experience with large single fraction as used currently in
SBRT protocols existed, with virtually no experience on
the optimal prescription method (homogenous vs. inho-
mogenous dose distribution, level of inhomogeneity).
Herein, we report on a single institutional experience in
treatment of liver metastases by hypofractionated stereo-
tactic radiotherapy (SBRT) in patients not eligible for
surgical treatment. A normal-tissue adapted planning con-
cept has been applied, using an inhomogenous dose pre-
scription to the 60% isodose line covering the planning
target volume, allowing a steep concentric dose built-up
within the tumor.
Patients and methods
Patient eligibility
From December 2000 to September 2009, 76 patients
with 95 metastatic lesions in the liver not eligible for
surgical resection due to local tumor extension and/or
patients comorbidities have been treated with SBRT at
our institution. Indication for treatment included locally
progressive liver disease which was not amenable to
other local therapy, or progressive after chemotherapy
and considered the predominant tumor burden endan-
gering the patient in the short term. Therefore, besides
patients with no evidence of extrahepatic disease, pa-
tients with stable or progressive extrahepatic disease
were considered for liver SBRT as well. Patients with 1–
4 liver metastases irrespective of histology were eligible
after discussion in a multidisciplinary tumorboard,
which had recommended against other treatment mo-
dalities including surgery.
Pretreatment investigations in all patients consisted of
physical examination, laboratory tests including blood
counts and liver enzymes, computed tomography (CT)
scan of the thorax and abdomen with i.v. contrast and -
in selected patients - whole body positron emission tom-
ography (PET, Tracer: 18-F-fluorodeoxyglucose (FDG))
on a dedicated combined PET/CT hybrid scanner.
Radiation treatment planning and delivery
Immobilization for image acquisition and treatment
was carried out in a vacuum couch with a low-pressure
foil (Medical Intelligence GmbH, Schwabmünchen,
Germany). An abdominal compression device was used
which aimed at reducing the motion of the diaphragm.
During CT scanning and irradiation patients received
oxygen supply to further reduce respiratory motion.
Gross tumor volume (GTV) was contoured as the visible
tumor in the planning CT supplemented by information
from magnetic resonance imaging (MRI). No separate
CTV margin was applied (i.e. GTV =CTV). Breathing mo-
tion was taken into account by sequential CT scans to de-
rive an individual margin for each patient. This internal
target volume was complemented by an additional margin
of 5 mm (axial dimension) and 10 mm (longitudinal di-
mension) to account for reproducibility of patient
positioning.
After January 2009, patients (n = 15) additionally re-
ceived a 4D-CT and a respiration correlated PET scan in
treatment position. All imaging modalities (planning CT,
MRI, 4D-PET-CT) were then fused using iPlanNet V4
(Brainlab AG, Feldkirchen, Germany) and a composite
GTV contour was generated using the image informa-
tion on macroscopic tumor from all image modalities.
PTV margins consisted of the tumor motion in all
dimensions as derived from the 4D-PET-CT comple-
mented by an isotropic margin of 5 mm in all directions
to account for setup uncertainties.
Treatment consisted of 3–5 fractions with 5–12.5 Gy
per fraction prescribed to the surrounding 60-95% iso-
dose (median 35 Gy in 5 fractions to the 60% isodose)
using 5–8 coplanar open static fields. The most common
regimens were 35 Gy in 5 fractions (44 lesions; Dmax =
58.3 Gy, BED = 126 Gy10), 30 Gy in 3 fractions (10 le-
sions; Dmax = 50 Gy, BED = 133 Gy10), 37.5 Gy in 3 frac-
tions (8 lesions; Dmax = 62.5 Gy, BED = 193 Gy10) and
30 Gy in 5 fractions (5 lesions; Dmax = 50 Gy), all pre-
scribed to the 60% isodose line. The following consider-
ations led us to prescribe to a lower isodose line
compared to other groups. At the time this study was
initiated, scarce evidence for any fractionation and pre-
scription mode was available (year 2000). Therefore we
hypothesized that at the PTV margin an EQD2Gy of
50–70 Gy, depending on the fractionation schedule ap-
plied, should be sufficient to control microscopic disease
and a steep concentric dose increase should allow for
significantly higher doses within the tumor. At the same
time, a more rapid dose fall off outside the target may
facilitate adherence to normal tissue constraints. When-
ever feasible with regards to normal tissue constraints,
the 60% isodose line had to fully cover the PTV. Other-
wise, minimum dose to the PTV and corresponding pre-
scription isodose line were chosen depending on the
given dose constraint for the gastrointestinal tract and
liver: Dmax (bowel, stomach): 5×5.4 Gy or 3×7.0 Gy,
Dmax (esophagus): 5×6Gy or 3×9 Gy, D33% (liver) <
5×3.5 Gy or <3×5 Gy.
Positioning of the immobilized patient and target
localization was verified by additional CT scans with
subsequent transport of the patient within the
immobilization couch to the linac (before July 2008), or by
Cone Beam CT (after July 2008) before every treatment
fraction.
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Follow-up
During treatment, all patients were monitored daily for
acute treatment related toxicity. Follow-up 6 weeks after
completion of SBRT and every 3–4 months thereafter in-
cluded blood count, serum liver parameters and CT
and/ or MRI scans until tumor progression.
Acute toxicity was scored according to the National
Cancer Institute CTCAE v3.0 criteria during and up to
3 months after radiotherapy. Late toxicity was graded
using the RTOG/EORTC criteria.
Local failure of a metastatic lesion was defined as ei-
ther reappearance after complete remission or re-growth
after initial partial response in follow-up CT or MRI
scans.
Extrahepatic tumor status was classified as either no
evidence of disease (NED), stable (SD) or progressive
disease (PD).
Statistical analysis
Actuarial survival time and time to other endpoints were
calculated according to the Kaplan-Meier method. For
univariate and multivariate analysis of prognostic factors
Cox proportional hazard model was used. For overall
survival any death and for disease specific survival death
from the underlying cancer was defined as an event. For
actuarial local tumor control, progression of the treated
lesion was defined as stated in the Methods section. For
this endpoint, patients who died from other diseases
without tumor regrowth or progression at that time
were censored. All time intervals were calculated from
the last day of SBRT. Biological effective dose was calcu-
lated according to the LQ formalism: BED = n * d * (1 +
d/ {α/β}) with n being the number of fractions, d the
daily single fraction dose and alpha-beta for tumor tissue
of 10 Gy.
Comparison of survival between groups was per-
formed using the log-rank test. Statistical analysis was
performed with PASW Statistics V18 (SPSS Inc./IBM,
Somer, NY) and the R statistical environment version
2.12.2.
Results
This analysis included 38 male and 36 female patients
with a median age of 61 years (range 40–80 years). Two
patients with 2 liver metastases each had to be excluded
as they were lost to follow up immediately after radio-
therapy. Of the 95 lesions, 91 were evaluable for local
control and 89 for the influence of tumor volume
(GTV) and dose on local control. Table 1 summarizes
the patient and treatment characteristics. The median
Karnofsky performance status (KPS) was 90 (range 50–
100). 37 patients had colorectal cancer (50%), 12 patients
breast cancer (16%), and 25 patients other primary tu-
mors (34%). Thirty-five patients (47%) either had
extrahepatic stable or progressive disease, the remainder
showed no evidence of disease outside the liver. SBRT
was the initial treatment of liver metastases in 23 of 91
lesions (25%). Forty-four metastases (48%) were previ-
ously exposed to chemotherapy and 3 (3%) to endocrine
treatment. Resection, other local ablative procedures or
combinations of these had been performed in the
remaining cases. Of these 68 pre-treated lesions 47
showed clinical progression before SBRT, while 21 were
irradiated for residual lesions as identified on CT or
MRI. The median GTV size was 45 cc (range 1.3-
699 cc). The median PTV size was 123 cc (range 11–
1074 cc). In 10 patients (13.5%) more than 1 target
volume was irradiated. All patients completed their
planned course of SBRT. Median follow-up was
15 months. Forty-two patients (56.7%) had died at the
time of this analysis.
Local control
Median local recurrence free interval for all patients was
23 months with a local control rate of 74.7%, 48.3% and
48.3% after 1, 2 and 3 years, respectively (Figure 1). Only
minimal biologically effective dose (either to GTV {p <
0.0001} or PTV {p = 0.01}) and tumor volume (p = 0.03)
were predictive for local control in univariate analysis
(Table 2). In multivariate analysis only the minimal BED
to the GTV remained as independent prognostic factor
for local control of the irradiated lesions (p = 0.015). No
local recurrences were observed in lesions (n = 12) which
received a minimal BED to the GTV of 120 Gy.
Pattern of failure
Of 44 patients with tumor progression in the liver, 26
had local recurrences of SBRT treated metastases. Of
the 44 patients, 24 showed intrahepatic failure only. An-
other 23 patients developed extrahepatic progression
only. Overall, 67 patients (91%) showed disease progres-
sion after SBRT after a median time of 5 months
(Table 3).
Survival
Median overall survival was 27 months with survival
rates of 77%, 30% and 27% at 1, 3 and 5 years (Figure 1).
Eleven patients survived more than 36 months after
SBRT. In univariate survival analysis extrahepatic dis-
ease status (NED/SD vs. PD; p = 0.005), colorectal pri-
mary (p = 0.04) and smaller GTV volume (p < 0.001)
were correlated significantly with better overall survival
(Table 2). On multivariate analysis only GTV volume
remained as independent significant prognostic factor
for overall survival (p = 0.002).
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Toxicity
Treatment was very well tolerated with only grade 1–2
acute side effects including predominantly fatigue
(20.3%), nausea and vomiting (17.7%), fever (6.8%), skin
reaction (5.4%) and upper abdominal pain (8.1%). Rare
events included grade II pneumonitis (n = 1; antibiotic
and steroid therapy) and cholecystitis (n = 1; antibiotic
therapy). No grade 3 to 5 acute toxicity occurred
(Table 4).
Relevant long-term complications included pneumonitis
grade 2 (n = 2), skin ulcer (n = 1; grade 2, local surgery re-
quired; thoracic wall infiltration by the metastases) and rib
Table 1 Patient and treatment characteristics
Patients
No. of patients evaluable/completing treatment 74/76
Gender Male 38
Female 36
Age at treatment (years) Median 61 (range 40-80)
ECOG performance status Median 0 (range 0-2)
0 50
1 22
2 2
Status of extrahepatic disease
NED (no evidence of disease) 39 (53%)
SD/PD (stable/progressive) 35 (47%)
Previous treatment per irradiated lesion
No previous treatment 23 (25.3%)
Chemotherapy 44 (48.4%)
Endocrine therapy 3 (3.3%)
Local therapy (surgery, radiofrequency ablation) 4 (4.4%)
Combination of local and systemic treatment 17 (18.6%)
Follow up (months) Median 15 (range 3-103)
Primary tumor Colorectal 37
Breast 12
Esophageal 5
Stomach/Pancreas/Bile duct 7
Lung 2
Other 11
Lesions
Total No. of lesions evaluated/treated 91/95
Lesions per patient Mean 1.23 (range 1-4)
Total PTV dose at 60-95% IDL Median 35 (range 18-37.5)
(Gy)
Single PTV dose at 60-95% IDL Median 7 (range 5-12.5)
(Gy)
Fractions Median 5 (range 2-5)
Minimum BED to GTV Median 91.2 Gy (18.7-183.5Gy)
Gross tumor volume GTV (cc) Median 45 (range 1.3-699)
<100 65
100-200 12
>200 12
Planning target volume PTV (cc) Median 123 (range 10.6-1074)
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fractures (n = 5; only analgetics necessary). No grade 4 or
5 late toxicity occurred.
Discussion
So far, surgical resection is still considered the gold
standard for operable liver metastases in functionally op-
erable patients, if a significant benefit with regard to
quality of life and overall survival is to be expected
[14,15]. Still, not all patients presenting with a limited
number of liver metastases in an oligometastatic setting
are suitable candidates for resection. Over the past two
decades several local ablative therapies have emerged,
with radiofrequency ablation being the most widely used
[16]. In recent years, SBRT - originally developed for ab-
lative high-precision radiotherapy of brain tumors – has
been adopted for treatment of primary or secondary
tumors of the lung and liver. Our institution started liver
SBRT in December 2000. Patients were referred by one
of the hospital’s multidisciplinary tumor boards, typically
either the gastrointestinal or breast cancer board. Most
patients were pre-treated for their liver metastases and
had quite large lesions but were in good general condi-
tion (Table 1). Here we report on long-term follow-up of
all patients treated during the first 9 years.
Our retrospective analysis suggests that both long-
term local control and survival is possible, although a
significant proportion of patients relapsed outside and
inside of the irradiated region. Acceptable toxicity rates
and pattern were seen, despite treatment of multiple
and/or large lesions in many patients (no radiation-
induced liver disease). The latter was also the case in the
phase II trial recently reported by Scorsetti et al. [17].
They had treated 61 patients with 76 lesions (3 fractions)
and observed excellent local control and survival at 1 year
(both >80%). In a variety of other publications, results
were largely comparable, as summarized in Additional file
1: Table S1 [8-13,17-21]. In the phase I portion of a trial
reported by Rusthoven et al., dose was escalated from
36 Gy to 60 Gy in three fractions, in increments of 6 Gy,
without dose-limiting toxicity [11]. In the phase II compo-
nent, the dose was 60 Gy in three fractions prescribed to
the 80-90% isodose line. Thirteen patients were treated to
doses less than 60 Gy, and 36 patients received 60 Gy. For
lesions with maximum diameter of 3 cm or less, 2-year
local control was 100% compared with 77% for lesions
greater than 3 cm (p = 0.015). Berber et al. have recently
evaluated a multicenter database from 4 academic medical
centers in the United States (April 2000 - September 2010,
different techniques, total dose 37.5 ± 8.2 Gy in 5 ± 3
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Figure 1 Kaplan-Meier estimates for overall survival (upper left panel), stratified by GTV volume (lower left panel), local control (upper
right panel), stratified by BED to the GTV (lower right panel). Bounding curves in the upper panel represent the 95% confidence interval.
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fractions, 70% isodose line) [22]. They reported on 153
patients (363 tumors, most primaries were of colorectal or
breast origin). The mean GTV size was 138 cc, range 8–
581 cc). Mean follow-up was 25 months. One-year sur-
vival was 51% (77% in our study) and local control was
62% (75% in our study). Grade 3 and 4 toxicity was ob-
served in 3% of patients (no deaths from SBRT). These
results support our own and various previous studies,
demonstrating that SBRT is a safe technique for the pre-
cise delivery of radiation to liver tumors.
Chang et al. reported on a pooled patient cohort treated
with SBRT for colorectal liver metastases (1–4 lesions, 1–
6 fractions of SBRT) [23]. Their series included 65 patients
with 102 lesions from 3 institutions. The median follow-
up was 1.2 years. Total dose, dose per fraction and BED all
correlated with local control. The estimated dose range
needed for 1-year local control >90% was 46–52 Gy in 3
fractions. We have also seen favorable local control in all
metastases treated to a high BED (BED of greater than
120 Gy with an alpha/beta of 10 Gy). However, dependent
on size, number of targets and dose-limiting normal tis-
sues such high BED cannot always be achieved. Under
these circumstances, SBRT to lower doses might still pro-
vide valuable palliation, preventing for example biliary ob-
struction. Given that most patients progress somewhere in
the liver or in other organs within 12 months, it is clear
that local measures cannot be considered curative in the
majority of patients. Predictive factors are needed to iden-
tify those patients who are unlikely to relapse at other sites
and for whom optimal local control is a prerequisite for
long-term survival, comparable to selection criteria for
surgical candidates. Most likely, these factors vary with
primary disease type or even subgroup as in the case of
colorectal (isolated metastases in the liver) and breast can-
cer (triple negative, Her2 positive etc.), making it necessary
to perform much larger studies than hitherto. It is also im-
portant to define the dose–response relationships and
Table 2 Univariate and multivariate analysis for local control and overall survival according to patient and tumor
characteristics (§primary treatment vs progression after pretreatment; &complete remission/stable disease vs
progressive disease; *colorectal cancer vs. other; **volume and minimum biologically effective dose as continuous
variables; ECOG performance status 0 vs. 1-2; abbreviations: GTV=gross tumor volume, PTV=planning target volume,
PS= performance status, HR=hazard ratio, CI=95% confidence interval)
Local control
Univariate Multivariate
HR (CI) p-value HR (CI) p-value
Indication for SBRT§ 0.91 (0.42-1.99) 0.82 0.97 (0.35-2.72) 0.96
Prior CTx 0.66 (0.25-1.79) 0.42 0.33 (0.08-1.30) 0.11
Histology* 1.69 (0.72-3.98) 0.22 1.58 (0.61-4.10) 0.35
GTV Volume** 1.003 (1-1.005) 0.03 1.002 (0.99-1.004) 0.27
BED PTV** 0.95 (0.92-0.99) 0.01 0.98 (0.93-1.03) 0.38
BED GTV** 0.97 (0.96-0.99) <0.001 0.98 (0.96-0.996) 0.015
Overall survival
Univariate Multivariate
HR (CI) p-value HR (CI) p-value
ECOG PS 0.71 (0.38-1.34) 0.29 0.92 (0.53-2.25) 0.83
Histology* 0.53 (0.29-0.98) 0.04 0.65 (0.32-1.34) 0.25
Prior CTx 0.58 (0.26-1.33) 0.19 0.70 (0.26-1.87) 0.47
Extrahepatic disease status before SBRT& 2.5 (1.3-4.8) 0.005 1.69 (0.81-3.51) 0.16
GTV Volume** 1.003 (1.001-1.004) <0.001 1.003 (1.001-1.004) 0.002
Local recurrence after SBRT 0.80 (0.42-1.52) 0.5 0.70 (0.34-1.48) 0.35
Table 3 Patterns of failure and treatment of progression
after index treatment
Total (n=74)
Dead 42
Any disease progression 67
Local progression at treated site 26
Location of first progression
Liver only 24
Liver and other organs 20
Other organs only 23
Treatment for first progression
Local Treatment 17
Chemotherapy 43
Others 7
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optimal fractionation regimens in a more concise and de-
finitive manner. Randomized trials comparing different
fractionation schedules and even well-designed prospect-
ive phase-II-trials are still lacking. Given our toxicity data,
it appears safe to use the dose constraints that we applied,
i.e. Dmax (bowel, stomach): 5x5.4 Gy or 3x7.0 Gy, Dmax
(esophagus): 5x6Gy or 3x9 Gy, D33% (liver) < 5x3.5 Gy or
<3x5 Gy. However, as local and locoregional control rates
need to be further improved, alternatives might also be
considered, for example the dose constraint that 700 cc of
normal liver would receive less than 15 Gy, to allow a fur-
ther dose escalation to the metastatic lesions. Rusthoven
et al. recommended a maximum total dose to any point in
the spinal cord and stomach/small intestine not to exceed
18 Gy and 30 Gy, respectively (3 fractions) [11]. Import-
antly, one should recognize that true long-term toxicity is
not well defined because published series have short me-
dian follow-up and few long-term survivors.
SBRT proved as an effective local treatment option for
technically and medically inoperable patients with up to
4 liver metastases without major side effects observed so
far. Even when large tumors or metastases in very crit-
ical locations within the liver have to be treated by
SBRT, and very strict dose constraints are used for ra-
diosensitive structures and organs, a respectable local
control rate can be achieved. Side effects have not been
critical and treatment was very well tolerated. Local con-
trol was mainly influenced by lesion size and radiation
dose, while overall survival was predominantly affected
by lesion size and extrahepatic disease control. Unfortu-
nately, systemic progression still limits long-term sur-
vival in this poor prognostic group.
Conclusion
Based on these initial results after implementation of
liver SBRT, it seems reasonable to treat up to 4 metasta-
ses regardless of tumor volume in ablative intent as long
as normal tissue constraints are respected, as even pa-
tients with large tumor volumes can achieve substantial
survival after SBRT. Nevertheless, if the tumor volume
(based on GTV) as the single most important factor pre-
dicting overall survival exceeds 100 cc (approx. 6 cm
diameter) or a sufficient GTV dose cannot be achieved
(<120Gy BED), realistic treatment aims have to be com-
municated to the patient (temporary response, limited
prolongation of survival).
Additional file
Additional file 1: Table S1. Comparison with published international
results [8-13,17-21].
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Table 4 Acute and late side effects according to CTCAE
v3.0
Acute toxicity Grade 1-2
GI tract 17 (23%)
Nausea 10 (13.6%)
Vomiting 3 (4.1%)
Inappetence 1 (1.4%)
Diarrhea 0
Obstipation 2 (2.7%)
Meteorism 1 (1.4%)
Skin reaction 4 (5.4%)
Fatigue 15 (20.3%)
Fever 5 (6.8%)
Abdominal pain 6 (8.1%)
Pneumonitis 1 (1.4%)
Cholecystitis 1 (1.4%)
Late toxicity Grade 1-2
GI tract 10
Nausea 4
Vomiting 1
Inappetence 3
Diarrhea 1
Meteorism 1
Skin reaction 5*
Fatigue 8
Abdominal pain 5
Pneumonitis 3
Rib fracture 5
(*One patient experienced skin reaction with a local ulcer which required
local excision).
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